Vigil Neuroscience (NASDAQ:VIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Vigil Neuroscience (NASDAQ:VIGL) issued its earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08), Zacks reports.

Vigil Neuroscience Trading Down 10.2 %

VIGL opened at $2.11 on Friday. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06. The company has a market capitalization of $86.25 million, a PE ratio of -1.02 and a beta of 1.82. The firm’s 50 day simple moving average is $2.34 and its two-hundred day simple moving average is $2.80.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VIGL shares. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. William Blair started coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating on the stock. JMP Securities restated a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, January 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience currently has an average rating of “Buy” and an average price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.